Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Assets: 2014-2025

Historic Assets for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $577.1 million.

  • Viridian Therapeutics, Inc.\DE's Assets fell 25.23% to $577.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $577.1 million, marking a year-over-year decrease of 25.23%. This contributed to the annual value of $742.4 million for FY2024, which is 51.38% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Assets of $577.1 million as of Q3 2025, which was down 0.89% from $582.3 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Assets ranged from a high of $771.9 million in Q3 2024 and a low of $118.2 million during Q2 2021.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's Assets had a median value of $582.3 million in 2025 and averaged $555.3 million.
  • Its Assets has fluctuated over the past 5 years, first soared by 573.73% in 2021, then declined by 25.38% in 2023.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Assets stood at $203.7 million in 2021, then soared by 113.58% to $435.1 million in 2022, then grew by 12.72% to $490.4 million in 2023, then spiked by 51.38% to $742.4 million in 2024, then decreased by 25.23% to $577.1 million in 2025.
  • Its Assets was $577.1 million in Q3 2025, compared to $582.3 million in Q2 2025 and $661.0 million in Q1 2025.